Work

Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma

Year: 2022

Type: erratum

Source: Clinical Drug Investigation

DOI: 10.1007/s40261-022-01132-y

Authors: Baek‑Yeol Ryoo, Daniel H. Palmer, Sook Ryun Park, Lorenza Rimassa, Debashis Sarker, Bruno Daniele, Joyce Steinberg, Beatriz López, Ho Yeong Lim

Institutions: Asan Medical Center, University of Ulsan, Liverpool Experimental Cancer Medicine Centre, Humanitas University, IRCCS Humanitas Research Hospital, King's College London, Regione Campania, Azienda Ospedaliera G.Rummo, Astellas Pharma (United States), Janssen (Netherlands), Astellas Pharma (Netherlands), Samsung Medical Center, Sungkyunkwan University

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4214743207

Cites:

Cited by:

Related to: 10